Specialty Practice Pharmacist, Infectious Diseases; PGY2 Infectious Diseases Residency Program Director
The Ohio State University Wexner Medical Center
368 Doan Hall
410 W. 10th Avenue
Columbus, Ohio 43210
614-685-1901
Lynn.Wardlow@osumc.edu
Professional Interests
I completed a PGY1 pharmacy residency at University of Arizona and PGY2 Infectious Diseases pharmacy residency at University of California-San Diego. Prior to my current role at the Ohio State, I was an infectious diseases clinical pharmacist at University of Louisville Hospital.
I received board certification as an infectious diseases pharmacist in 2015. My practice interests include HIV, fungal infections in immunocompromised hosts, global stewardship outreach, and optimizing transitions of care for patients on intravenous antimicrobials.
Education and Training
PharmD/MBA: Drake University
MS Clinical Pharmacology: The Ohio State University
PGY1 Pharmacy Residency: University of Arizona
PGY2 Infectious Diseases Pharmacy Residency: University of California-San Diego
American Society for Microbiology, 2012 – Present
Society of Infectious Diseases Pharmacists, 2011 - Present
Making a Difference in Infectious Diseases Pharmacotherapy, 2011 - Present
American College of Clinical Pharmacy, 2009 - Present
SIDP Infectious Diseases Pharmacotherapy Paper of the Year Award, 2022
OSU ID Fellowship Program Teacher of the Year Award, 2022
OSU College of Pharmacy Preceptor of the Year, 2022
Staff Career Development Grant Recipient, 2018
OSUWMC Residency Research Impact Award, 2018
University of Kentucky College of Pharmacy Statewide Preceptor of the Year, 2016
University of Louisville Hospital PGY1 Residency Program Preceptor of the Year, 2014
Gerlach AT, Hoyte BR, Cotten SW, Doepker BA, Murphy CV, Reed, EE, Smetana KS, Wardlow LC. Development of 8-h urine collections and an augmented renal clearance dosing program at an academic medical center. J Am College Clin. 2023. doi.org/10.1002/jac5.1818.
Booth JP, Aycock AC, Elefritz JL, Gaborcik JW, Wardlow LC, Loborec JD. A resident-preceptor collaboration to encourage wellness and reduce burnout amongst pharmacy residents. Am J Pharm Educ. 2023;87:100139.
Caputo R, Rozycki A, McClain M, Sobhanie MM, Coe K, Colburn N, Wardlow L. Clinical outcomes with ertapenem for pneumonia in obese versus nonobese patients. Antimicrob Agents Chemother. 2022;66(1):e01325-21.
Lorenz A, Sobhanie MME, Orzel L, Coe K, Wardlow L. Clinical outcomes of combination versus monotherapy for gram negative non-HACEK infective endocarditis. Diag Microbiol Infect Dis. 2021;101(3):115504.
Tossey JC, El Boghdadly Z, Reed EE, Dela-Pena J, Coe K, Williams SN, Wardlow LC. Oral fluoroquinolones for definitive treatment of gram-negative bacteremia in cancer patients. Support Care Cancer. 2021;29(9):5057-5064.
Agnello S, Wardlow LC, Reed E, Smith JM, Coe K, Day SR. Clinical outcomes of daptomycin versus anti-staphylococcal beta-lactams in definitive treatment of methicillin-susceptible Staphylococcus aureus bloodstream infections. Inter J Antimicrob Agents. 2021;58(2):106363.
Taylor AP, Coe K, Stevenson K, Wardlow L, Boghdadly ZE, Reed E. Clinical impact of an antibiotic time out initiative at an academic medical center. Hosp Pharm. 2021;56(4):343-346.
Nichols CN, Wardlow LC, Coe KE, Sobhanie MME. Clinical outcomes with definitive treatment of methicillin-resistant Staphylococcus aureus bacteremia with retained daptomycin and ceftaroline combination therapy vs de-escalation to monotherapy with vancomycin, daptomycin, or ceftaroline. Op Forum Infect Dis. 2021;8(7):ofab327.
Vlashyn OO, Lorenz A, Sobhanie MM, Smith JM, Bond M, Wardlow L. Safety outcomes with high-dose daptomycin in patients with acute kidney injury and/or end-stage renal disease. J Clin Phar Ther. 2021;46(2):363-368.
Holsen MR, Wardlow LC, Bazan JA, Fussner LA, Coe KE, Elefritz JL. Clinical outcomes following treatment of Enterobacter species pneumonia with piperacillin/tazobactam compared to cefepime or ertapenem. Inter J Antimicrob Agents. 2019;54(6):824-828.
Shah MD, Coe KE, El Boghdadly Z, Wardlow LC, Dela-Pena JC, Stevenson KB, Reed EE. Efficacy of combination therapy versus monotherapy in the treatment of Stenotrophomonas maltophilia pneumonia. J Antimicrob Chemother. 2019;74(7):2055-2059.
Shah MD, Wardlow LC, Stevenson KB, Coe KE, Reed EE. Clinical outcomes with penicillin versus alternative B-lactams in the treatment of penicillin susceptible Staphylococcus aureus bacteremia. Pharmacotherapy. 2018 May 25. doi: 10.1002/phar.2124
Arnold FW, Heishman C, Wardlow LC, Hummel L, Munier G, Snyder JW. A case of a metallo-B-lactamase producing Klebsiella pneumoniae in Louisville, Kentucky: how to prevent the next hospital outbreak of carbapenem-resistant Enterobacteriaceae. J Ky Med Assoc. 2014;112(2):23-29.
Phan H, Wardlow LC. Pediatric Immunizations. In: Katz MD, Matthias K, Chisholm-Burns M (eds). Pharmacotherapy Principles & Practice Study Guide: A Case-based Care Plan Approach. 2nd- 4th ed. New York: McGraw-Hill, 2011, 2013, 2016.